Hepatic resection compared to chemoembolization in intermediate‐ to advanced‐stage hepatocellular carcinoma: A meta‐analysis of high‐quality studies

According to the American Association for the Study of Liver Diseases (AASLD) treatment guidelines for hepatocellular carcinoma (HCC), the role of surgery has been expanded beyond the Barcelona Clinic Liver Cancer (BCLC) algorithm. We compared primary hepatectomy (PH) with transarterial chemoemboliz...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Hepatology (Baltimore, Md.) Ročník 68; číslo 3; s. 977 - 993
Hlavní autoři: Hyun, Myung Han, Lee, Young‐Sun, Kim, Ji Hoon, Lee, Chan Uk, Jung, Young Kul, Seo, Yeon Seok, Yim, Hyung Joon, Yeon, Jong Eun, Byun, Kwan Soo
Médium: Journal Article
Jazyk:angličtina
Vydáno: United States Wolters Kluwer Health, Inc 01.09.2018
Témata:
Carcinoma, Hepatocellular - mortality
Carcinoma, Hepatocellular - surgery
Chemoembolization, Therapeutic
Clinical trials
Hepatectomy
Hepatocellular carcinoma
Hepatology
Humans
Liver cancer
Liver diseases
Liver Neoplasms - mortality
Liver Neoplasms - surgery
Meta-analysis
Patients
Regression Analysis
Surgery
Survival
ISSN:0270-9139, 1527-3350, 1527-3350
On-line přístup:Získat plný text
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Popis
Shrnutí:According to the American Association for the Study of Liver Diseases (AASLD) treatment guidelines for hepatocellular carcinoma (HCC), the role of surgery has been expanded beyond the Barcelona Clinic Liver Cancer (BCLC) algorithm. We compared primary hepatectomy (PH) with transarterial chemoembolization (TACE) in patients with intermediate‐ to advanced‐stage (BCLC stage B/C) HCC to determine the current evidence. Through a database search, we included 18 high‐quality studies (one randomized controlled trial [RCT], five propensity‐score matching nonrandomized comparative trials [NRCTs], and 12 NRCTs) that compared survival outcomes of 5,986 patients after PH and TACE. We found significant survival benefits for PH over TACE in BCLC stage B/C patients (hazard ratio [HR], 0.59; 95% confidence interval [CI], 0.51‐0.67; P < 0.00001; I2 = 84%). According to the BCLC, both stage B and stage C patients showed significantly better overall survival (OS) for PH compared to TACE (HR, 0.53; 95% CI, 0.43‐0.65; P < 0.00001; I2 = 77%; HR, 0.67; 95% CI, 0.59‐0.77; P < 0.00001; I2 = 79%, respectively). Five‐year survival rates for PH were significantly higher than those for TACE in BCLC stage B/C, stage B, and BCLC stage C patients (odds ratio [OR], 2.71, 2.77, and 3.03, respectively; all P < 0.00001). Survival benefits persisted across subgroup, sensitivity, and metaregression analyses; interstudy heterogeneity remained constant. Conclusion: This meta‐analysis suggests that surgical resection provides survival benefits in patients with intermediate‐ to advanced‐stage HCC. The evidence found herein may assist in the choice of treatment modality based on diverse definitions of operability. (Hepatology 2018).
Bibliografie:These authors contributed equally to this work.
Potential conflict of interest: Nothing to report.
This study was funded by a National Research Foundation of Korea grant from the Korean government (the Ministry of Education, Science and Technology; 2015R1C1A1A01052360) and an academic research fund of the Korean Liver Cancer Study for 2016.
ObjectType-Article-2
SourceType-Scholarly Journals-1
content type line 14
ObjectType-Feature-3
ObjectType-Evidence Based Healthcare-1
ObjectType-Feature-1
content type line 23
ObjectType-Undefined-3
ISSN:0270-9139
1527-3350
1527-3350
DOI:10.1002/hep.29883